Ian Mortimer is CEO & President at Xenon Pharmaceuticals Inc. (XENE). They have made 7 open-market trades across 1 company since 2016, most recently 2026-09-30.
CIK 0001619961
3 open-market purchases totalling $1.2M since 2016, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XENE | 49,923 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2026-10-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XENE | BUY | 2026-09-30 | 2026-10-01 | $37.38 | $1.1M | -11.2% | — | — |
| XENE | SELL | 2026-03-13 | 2026-03-13 | $55.23 | $404K | +1.0% | +6.6% | -5.1% |
| XENE | SELL | 2026-03-09 | 2026-03-11 | $60.32 | $17.0M | -6.6% | +0.3% | -9.4% |
| XENE | SELL | 2026-01-02 | 2026-01-02 | $44.43 | $1.8M | -5.6% | -5.9% | +29.1% |
| XENE | SELL · 10b5-1 | 2025-12-05 | 2025-12-09 | $45.33 | $2.3M | +1.6% | -5.0% | +44.6% |
| XENE | SELL · 10b5-1 | 2025-11-28 | 2025-12-03 | $45.01 | $4K | -1.6% | +0.5% | -1.1% |
| XENE | SELL · 10b5-1 | 2025-10-01 | 2025-10-01 | $40.16 | $2.0M | +3.2% | +8.2% | +13.9% |
| XENE | SELL · 10b5-1 | 2025-01-23 | 2025-01-27 | $40.25 | $4.4M | -1.0% | -2.3% | -5.4% |
| XENE | SELL | 2023-05-24 | 2023-05-26 | $41.41 | $2.6M | +6.5% | -2.2% | -4.1% |
| XENE | BUY | 2017-08-10 | 2017-08-14 | $2.88 | $43K | +25.0% | +24.0% | -10.6% |
| XENE | BUY | 2016-06-24 | 2016-06-28 | $6.22 | $33K | +22.0% | +24.3% | +35.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.